Jinxin Fertility Listed At Hong Kong Exchange

After 4 months of initial application, Jinxin Fertility was finally listed at Hong Kong Exchange, A total of approximately 357 million shares were issued globally, of which 143 million shares were issued in Hong Kong and 214 million shares were issued internationally at 8.54 HKD per share.    

This round of financing through stock sales has raised 2.8 billion HKD, 25% of the funds will be used to recruit more medical professional, 40% of the funds will be used for future acquisition, 10% of the funds will be used for research, 15% of the funds will be used for promotion and the last 10% of the funds will be used for operations.  

In January 2017, Jinxin Fertility acquired Shenzhen Zhongshan Hospital and expanded its business to Guangdong. In addition, in December 2018, Jinxin Fertility acquired HRC Medical in California. In the success rate of IVF, Jinxin Fertility has reached 54% in China, higher than the national average of 45%.

According to the financial data, Jinxin Fertility's net profit was 103 million RMB, 198 million RMB and 250 million RMB in 2016, 2017 and 2018 respectively. The auxiliary reproductive market still has great potential. The prevalence of global infertility has risen from 11.0% in 1997 to 15.0% in 2017 due to environmental pollution, work-life imbalances and other reasons.